Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial.

MLA

Mitha, Essack, et al. “Rilonacept for Gout Flare Prevention during Initiation of Uric Acid-Lowering Therapy: Results from the PRESURGE-2 International, Phase 3, Randomized, Placebo-Controlled Trial.” Rheumatology, vol. 52, no. 7, July 2013, pp. 1285–92. EBSCOhost, https://doi.org/10.1093/rheumatology/ket114.

APA

Mitha, E., Schumacher, H. R., Fouche, L., Luo, S.-F., Weinstein, S. P., Yancopoulos, G. D., Wang, J., King-Davis, S., & Evans, R. R. (2013). Rilonacept for gout flare prevention during initiation of uric acid-lowering therapy: results from the PRESURGE-2 international, phase 3, randomized, placebo-controlled trial. Rheumatology, 52(7), 1285–1292. https://doi.org/10.1093/rheumatology/ket114

Chicago

Mitha, Essack, H. Ralph Schumacher, Leon Fouche, Shue-Fen Luo, Steven P. Weinstein, George D. Yancopoulos, Jian Wang, Shirletta King-Davis, and Robert R. Evans. 2013. “Rilonacept for Gout Flare Prevention during Initiation of Uric Acid-Lowering Therapy: Results from the PRESURGE-2 International, Phase 3, Randomized, Placebo-Controlled Trial.” Rheumatology 52 (7): 1285–92. doi:10.1093/rheumatology/ket114.